Life Sciences & Biomedicine Science & Technology Substance Abuse
Objectives:
Although HIV+ individuals may be at increased risk of alcohol-related cognitive impairment, the relations between drinking level and cognitive performance in these individuals are not well understood. We examined whether higher levels of recent drinking in HIV+ individuals were associated with poorer cognitive performance, particularly in executive functioning and memory.
Materials and Methods:
We administered a comprehensive cognitive battery to 120 seropositive subjects (101 men) who reported alcohol consumption in the preceding 90 days. Participants were excluded if they were seeking alcohol treatment or showed evidence of dementia. Using the computerized CogState battery, we measured performance in executive functioning, verbal learning/memory, visual learning/memory, attention, working memory, and psychomotor speed. The computerized Iowa Gambling Task was used to assess decision-making.
Results:
The HIV+ subjects showed significantly slower psychomotor speed than a normative sample. Although across most domains, neurocognitive performance in our sample was not significantly associated with recent alcohol consumption, performance on the CogState measures of visual memory and attention was significantly poorer with a higher level of drinking in the past 3 months and a current alcohol use disorder, respectively.
Conclusions:
Although cognitive weaknesses were detectable among these non-treatment-seeking HIV+ drinkers, the level of alcohol consumption was not a primary determinant of neurocognitive performance in this group. A comprehensive profile analysis may be most valuable for detecting cognitive strengths and weaknesses given the heterogeneity of this population. Longitudinal studies are needed to examine the potential additive or synergistic effects of heavy drinking and HIV seropositivity on cognitive performance.
Effects of Recent Alcohol Consumption Level on Neurocognitive Performance in HIV+ Individuals
Creators
Kara R. Douglas-Newman - Behavioral Health Services
Rachel V. Smith - Behavioral Health Services
Mary V. Spiers - Drexel University
Timothy Pond - Center for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, 3535 Market Street, Philadelphia, PA 19104.
Henry R. Kranzler - Behavioral Health Services
Publication Details
Addictive disorders & their treatment, v 16(3), pp 95-107
Publisher
Lippincott Williams & Wilkins
Number of pages
13
Grant note
AbbVie
XenoPort
P30 AI045008; K24 AA013736 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
Indivior
Pfizer
K24AA013736 / NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
Otsuka; Otsuka Pharmaceutical
Lilly; Eli Lilly
P30AI045008 / NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)
Ethypharm
Lundbeck; Lundbeck Corporation
Alkermes
Resource Type
Journal article
Language
English
Academic Unit
[Retired Faculty]
Web of Science ID
WOS:000416713800001
Scopus ID
2-s2.0-85020688858
Other Identifier
991019168329304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: